The company now projects 2026 revenue growth in the low-twenties percentage range, a notable jump from its previous guidance of low- to mid-teens. Adjusted earnings before interest, taxes, depreciation, and amortization are similarly expected to climb into the low- to mid-forties. This momentum is largely attributed to robust patient uptake and favorable pricing for Bimzelx, supported by steady performances from the legacy anti-inflammatory drug Cimzia.

ING analysts noted that the upgrade specifically highlights the strength of the company’s key asset. While UCB’s forecast excludes proceeds from the sale of an FDA priority-review voucher—which could provide a further single-digit percentage boost—the core operational performance remains the primary catalyst for market confidence. If current trading levels hold, the stock is on track for its largest single-day percentage gain in over twelve months.